In 1998 a large highly powered trial, the UK Prospective Diabetes Study (UKPDS), demonstrated that in type 2 diabetes several clinical endpoints were improved by better diabetic control. A 0.9% decrease in glycosylated haemoglobin (HbA1c) over ten years was associated with a 25% reduction in microvascular complications (P=0.0099) and a less impressive 16% reduction in myocardial infarction (P=0.052).1 With this evidence base, the pressure is on for physicians to improve the HbA1c of people with diabetes.
No takes yet. Share an insight, caveat, or question.
C M. B Edwards (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: